Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Male Hypogonadism Market was Valued at $2,594 Million in 2015, and Is Estimated to Reach $3,233 Million by 2022, Growing at a CAGR of 3.1% During the Analysis Period

Wednesday, February 15, 2017 22:59
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Research study says global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period, Ask for Sample@ http://www.researchbeam.com/male-hypogonadism-market/request-sample

Recent research added report on “Global Male Hypogonadism Market Overview, Analysis, Demand, Report, Trends, Growth and Research – Male Hypogonadism Market by Therapy (Testosterone Replacement therapy and Gonadotropin and Gonadotropin-Releasing Hormones Therapy (Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), and Gonadotropin-Releasing Hormone (GnRH))), Drug Delivery (Topical Gels, Injectables, Transdermal Patches, and Others), and Type (Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, and Others) – Global Opportunity Analysis and Industry Forecast, 2014-2022”

Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

The global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Globally, the prevalence for hypogonadism among men is on a rise at a rapid rate, and according to multiple studies, only 10–15% of patients receive treatment for this condition. Major factors that drive the market growth include high incidence of hypogonadism; rise in geriatric population; growth in awareness of hypogonadism & its treatment options; and increased risk of developing hypogonadism due to increased incidence of chronic lifestyle diseases such as diabetes and obesity. In March 2015, FDA issued cautions & warnings against use of testosterone products as a therapy, and ordered the manufacturers to change labels & add cautions on their packaging. From recent studies conducted by the FDA, there is a high risk of acquiring cardiovascular diseases due to the use of TRT, thus impeding the market growth during the forecast period. However, novel treatment options that are under developmental stage have shown positive results in terms of efficacy, and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to provide new opportunities in the future.

Read More@ http://www.researchbeam.com/male-hypogonadism-market

The global male hypogonadism market is segmented based on therapy, drug delivery, type, and geography. Based on therapy, it is bifurcated into testosterone replacement therapy (TRT), and gonadotropin and gonadotropin-releasing hormones therapy. Gonadotropin and gonadotropin-releasing hormones therapy is further sub-classified into LH, FSH, human chorionic gonadotropin (hCG), and GnRH. Based on drug delivery, it is classified into topical gels, injectables, transdermal patches, and others. Based on type, it is categorized into Klinefelter’s syndrome, Kallmann syndrome, pituitary disorders, and others. Based on geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

MALE HYPOGONADISM MARKET KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market, with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by therapy helps in understanding the various types of therapies used for the treatment of hypogonadism.
  • Comprehensive analysis of geographical regions is provided, which helps in determining the prevailing opportunities in these geographies.
  • Key players within the market are profiled and their strategies are analyzed thoroughly to determine competitive outlook of the global market.

Ask for Discount@ http://www.researchbeam.com/male-hypogonadism-market/purchase-enquiry

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:

5933 NE Win Sivers Drive, #205, Portland, OR 97220

Web: http://www.researchbeam.com/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.